Prototeomics Assignment Part 1: Proteomics is defined by one web site as the "complete set of proteins encoded by the genome of a given organism." 1 However, further research finds that a set of encoded proteins is actually called a proteome. Whereas, proteomics refers to the sequencing, labeling of proteins, and involves the recognition of both their "physiological and pathophysicalogical functions." 2 It is the labeling and sequencing of the genomes that is, therefore, said to revive the interest of proteomics throughout the scientific community. 3 Recognized in the scientific community as an exciting field of study, Proteomics serves the world by applying derived knowledge to clinical procedures. 4 Although proteomics is regarded only to be in its early stages of development, it has already been successful in drug discovery and development. Oxford Glycosciences PLC particularly outlines the relationship between proteomics and drug discovery. Outlining the effects of proteomics in the five stages of drug development and discovery, Oxford Glycosciences PLC quickly summarizes the usefulness of utilizing proteomics during: (1) Novel target identification, (2) Target validation, (3) Lead Selection, (4) Pre-clinical development, and (5) Clinical development.
5 First, during the target identification stage, proteomics is used to significantly detect proteins in patients with a range of particular ailments or disorders. 6 Further exploration of this simple description expands this to a much more complex relationship between proteomics and target identification. For example, the Prolexy proteomics process uses platforms, specifically named "Hy Net" and "Hy spec", in order to create pertinent data involving the protein interaction within a particular patient. 7 Therefore, this leads to the next phase in drug discovery and development, utilizing proteomics during Target Validation. Secondly, during drug development and discovery, proteomics is very useful during the target validation. As noted by Oxford Glycosciences PLC, proteomics is used to " [provide] information on the structure, biological role and molecular interaction of proteins involved in the disease." 8 In particular, Prolexy Pharmaceuticals utilizes a "Yeast- based screening, in vitro biochemical assays and, finally through mammalian cell structure culture functional screens." 9 Figure 1: Prolexy Pharmaceutical's yeast based screening tools In addition, for clarification purposes, biochemical assays are simply tools used "in molecular diagnostic testing, primarily for the detection of infectious and inherited diseases." 10 Aside from Prolexy Pharmaceuticals, other companies also utilize and develop proteomic analysis in drug development.
For instance, a few companies use the process called Phage display. The use of phage display is currently used by Dyak & Cambridge Antibody Technologies and, developed by another company called SurroMed. 11 As a type of proteomic analysis, a phage display creates profiles for particular proteins throughout.